Company intelligence / Profile preview
Kira Biotech
Brisbane (Fortitude Valley), Queensland, Australiakirabiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kira Biotech has developed novel monoclonal antibodies targeting activated immune cells, particularly anti-CD83 antibodies. The company’s approach aims to induce immune tolerance and restore homeostasis in patients with autoimmune or immune-related conditions. As of the latest information, their lead assets are at the preclinical stage. No published clinical results yet.
- Therapeutic areas
- Immunology
- Modalities
- Monoclonal antibodiesImmunomodulatory compounds
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kira Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kira Biotech.